Clinical Trials Browser

Phase 3 × Active not recruiting × Bevacizumab × Clear all

NCT00217737 2026-03-18

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Phase 3 Active not recruiting

2,431 enrolled 13 charts

Gastrointestinal

Colonic Neoplasms

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

Neuroendocrine Tumors

NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Active not recruiting

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT02997228 2026-03-18

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03847428 2026-03-06

EMERALD-2

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3 Active not recruiting

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

403 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT04094688 2026-03-03

SOLARIS

Phase 3 Active not recruiting

455 enrolled 13 charts

Gastrointestinal

Colorectal Adenocarcinoma

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04712643 2026-01-30

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04854668 2026-01-30

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT03778957 2026-01-16

EMERALD-1

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04649489 2026-01-15

TALENTOP

Phase 3 Active not recruiting

Venous Thrombosis

NCT03148418 2026-01-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT05112965 2026-01-07

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT05904886 2025-12-31

SKYSCRAPER-14

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase 3 Active not recruiting

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04982237 2025-11-19

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03520686 2025-10-16

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3 Active not recruiting

831 enrolled 2 FDA

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT03828227 2025-07-18

COLAGE

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03390686 2025-05-31

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04732598 2025-02-05

AMBITION

Phase 3 Active not recruiting

Breast Neoplasms

NCT03737643 2025-01-29

DUO-O

Phase 3 Active not recruiting

1,407 enrolled 2 FDA

Ovarian Neoplasms

NCT05118776 2024-10-31

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Phase 3 Active not recruiting

Glioblastoma

NCT03635021 2024-10-21

CR-SEQUENCE

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT01910610 2024-03-12

STRATEGIC-1

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Cancer Metastatic